“…Eight (20.5%) studies were conducted only on healthy volunteers ( Akazawa et al, 2010 , He et al, 2021 , Hofer et al, 2010 , Jin et al, 2019 , Kamali et al, 2014 , Kammen et al, 2016 , Maleki et al, 2012 , Staempfli et al, 2007 ), seven (17.9%) in patients affected by genetic conditions (e.g., albinism, congenital achiasma, Leber’s hereditary optic neuropathy) ( Ather et al, 2019 , Davies-Thompson et al, 2013 , Lecler et al, 2018 , Manners et al, 2022 , Puzniak et al, 2019 , Puzniak et al, 2021 , Takemura et al, 2019 ), three (7.7%) in patients affected by ophthalmological pathologies (e.g., amblyopia, aniridia, glaucoma) ( Allen et al, 2018 , Altıntaş et al, 2017 , Miller et al, 2019 ), nineteen (48.7%) in patients with tumors or other expansive processes ( de Blank et al, 2013 , Ge et al, 2015 , Hajiabadi et al, 2015 , Hajiabadi et al, 2016 , Ho et al, 2019 , Hodaie et al, 2010 , Jacquesson et al, 2019a , Liang et al, 2021 , Lin et al, 2018 , Lober et al, 2012 , Ma et al, 2016 , Salmela et al, 2009 , Tao et al, 2009 , Wu et al, 2019 , Yoshino et al, 2016 , Zhang et al, 2012b , Zolal et al, 2017 ), one (2.6%) in patients affected by demyelinating disorders (e.g., multiple sclerosis, neuromyelitis optica) ( Techavipoo et al, 2009 ), and two (5.1 %) in patients with other pathologies (traumas, epilepsy) ( Lacerda et al, 2021 , Yang et al, 2011 ) .…”